At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 319 enrolled
Drug / intervention
Duvelisib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (DUO)
In Brief
A Phase 3 clinical trial evaluating Duvelisib and Ofatumumab for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. Completed, enrolled 319 participants across 92 sites in 11 countries.
Detailed Summary
A Phase 3 clinical trial to examine the efficacy of duvelisib monotherapy versus ofatumumab monotherapy in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Austria, Belgium, France, Germany, Hungary, Italy, New Zealand, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartNov 2013
First PostedDec 2013
Primary CompletionMay 2017
Study CompletionJun 2021
TodayJul 2026
First PostedDec 9, 2013
Enrollment StartNov 1, 2013
Primary CompletionMay 19, 2017
Study CompletionJun 1, 2021
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 12.6 years ago
Interventions
Duvelisibdrug
PI3K Inhibitor
Ofatumumabdrug
monoclonal antibody